Delivery Order SPE2DB22D1017-SPE2DB25FF6PD

Award Date 2/27/25
Potential Completion Date 2/28/25
Potential Value $7.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,449.87 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used in the management of diabetes. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $9,112.59, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication, to support military healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,382.18 Firm Fixed Price Delivery Order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an Ultimate Completion Date of October 22, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,016.37 firm-fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat diabetes. The contract has an ultimate completion date of November 14, 2024. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,133.91 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of May 2, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,880.52 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of May 14, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen...
This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,134.05 firm fixed-price delivery order is for the purchase of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,449.36, is a firm fixed-price delivery order for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to manage diabetes. The contract has a performance period through November 3, 2023 and was awarded on November 2, 2022. This award is part of a larger $999,999,999 Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,146.23 Firm Fixed Price Delivery Order contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of January 7, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,417.29 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF6PD
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,653.31, is a delivery order for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes.

The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/1/25, 3:29 AM